Tagged with Opinion

Europe Rainer Westermann of European life science venture capital lobby group, the Life Sciences Acceleration Alliance, lays out a policy roadmap for how innovative European pharma can continue to grow and thrive against a backdrop of trade uncertainty and precarious US-EU relations.   The US/EU trade deal was presented as necessary…

China This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Legend Biotech’s planned secondary listing, Betta’s Hong Kong IPO move, iRegene’s USD 40mn raise after FDA Fast Track for its Parkinson’s cell therapy, and Rapafusyn’s USD 44mn Series A for molecular glues. On the clinical front, Junshi posts positive…

UK Writing in the September 2025 edition of DIA’s Global Forum magazine, Janet Messer, Catherine Blewett, and Naho Yamazaki of the UK Health Research Authority (HRA) and Stephen Lam, Crina Cacou, Anthony Carter, and Sara Rajendran of the UK Medicines and Healthcare products Regulatory Agency (MHRA), lay out how UK clinical…

Japan Writing in the September 2025 edition of DIA’s Global Forum magazine, Seiko Usami, Shinichi Noda, Daisuke Koga, and Naoyuki Yasuda of the Pharmaceuticals and Medical Devices Agency (PMDA), Japan’s regulatory body, outline the benefits for global pharma of including Japan in their drug development activities.   Japan is one of…

Global Ahead of the 50th anniversary of the World Health Organization’s Model List of Essential Medicines (EML) in 2027, Brendan Shaw explains how the EML has evolved from a basic guide for low-income countries to a global benchmark shaping universal health coverage. Looking at the recently-published 2025 update, Shaw examines the list’s…

China This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Novartis’ USD 5.4bn expansion with Argo in cardiovascular siRNA, Hengrui’s USD 1.1bn out-licensing of its cardiac myosin inhibitor, Novatim’s USD 1.15bn ADC deal with Radiance, Convalife’s Hong Kong IPO filing, and Fosun’s TYK2/JAK1 rights buy. On the clinical side,…

UK Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France have the talent, capital, and healthcare ecosystems to lead. By linking their world-class clusters, aligning regulation, and pooling investment, they…

China Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting products to building real global brands means investing in strategic international talent acquisition and well-defined roles, all underpinned by a…

Europe The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains rocky, communication is patchy, and the wider impact on access and innovation is still murky. Writing in DIA’s Global Forum…

Africa Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold, a consultant to the Gates Foundation, unveil the “Continental List of Human Medicinal Products” pilot—a first-of-its-kind initiative led by the…

Global Writing in the July 2025 edition of DIA Global Forum, Samantha Holmes, Fiona Adshead, and Keith Moore of the Sustainable Healthcare Coalition explore how cross-sector partnerships are advancing environmental sustainability in healthcare. They highlight real-world examples—from GSK’s Carbon Neutral Lab to the SMI Health Systems Task Force; showing how collaboration…

Global Alzheimer’s Disease takes a heavy toll; not just on patients and caregivers, but on society as a whole. As populations age, this complex and often-stigmatised condition is becoming harder to ignore. Despite recent breakthroughs, we are still far from having the right tools: better diagnostics, effective treatments, and smarter healthcare…